EndoChoice Announces Health Canada License for Fuse Endoscopy System in Canada
Through its latest Canadian Association of Gastroenterology Survey of Access to GastroEnterology (SAGE) completed this April, results reveal a worrisome trend of longer wait times. Data was gathered from nearly 200 participating gastroenterologists who submitted information on approximately 2,000 patient interactions within the health system. SAGE surveys were also conducted in 2005 and 2008 . Over a seven-year period, the trend in longer wait times is evident according to soon to be published 2012 SAGE data. “Our analysis shows that patient wait times are now 30 days longer than they were in 2005,” says CAG Dr. Desmond Leddin, Lead on the CAG SAGE program. “This is a disturbing trend, and one which indicates a need to pursue strategies to ensure patients receive the digestive care they need in a more timely manner.” As an example, the recent SAGE data shows that a patient with a high likelihood of severe Inflammatory Bowel Disease (IBD) can expect a total wait time of 126 days. Of these 126 days, patients wait on average 72 days for a consultation and 44 days for a diagnostic endoscopy. Given the target total wait time of 14 days for this disease category, these patients are waiting 16 weeks longer than the recommended wait time target. (See fact sheet ) “The gap between current wait times and the desired target is too wide and wait times are getting longer,” says Dr. Dan Sadowski, President of the CAG. “In human terms, what this means is that many patients live with pain and some are unable to work or attend school and can only do so with difficulty while waiting for consultation and treatment.” This year, the WTA report is shedding more light on the total wait time(i) Canadians can experience in receiving necessary medical care. Thanks to the total wait times data collected and provided by CAG, the WTA report is now more comprehensive than ever. “The CAG has been a source of robust information for our expanded focus on wait times”, says Dr. Chris Simpson, Chair, Wait Time Alliance.
The Health Canada license means Fuse will be the first endoscopy system available with expanded viewing capabilities to reach Canadian patients. Endoscopes are thin flexible tubes with imaging capabilities that doctors use to view the upper and lower GI tracts of their patients. (Photo: http://photos.prnewswire.com/prnh/20140114/CL44806 ) The Fuse endoscopy system is comprised of colonoscopes and gastroscopes with multiple imagers enabling doctors to see more of the GI tract for diagnosis and treatment. Standard, forward-viewing endoscopy systems have a single imager so clinicians are switching to the Fuse system in an effort to improve the quality of their procedures. Caption: The Fuse colonoscope provides a field of view of 330 degrees versus 170 degrees from standard endoscopes. In clinical studies, the Fuse system identified 70% more polyps than traditional colonoscopies. Being able to see more anatomy may allow doctors to find more pre-cancerous polyps like the one in the right screen of this image. The news from Health Canada enables EndoChoice to begin delivering Fuse endoscopy systems to their gastroenterology specialist customers throughout Canada. “We intend to gain market clearance in several more countries in the near future,” said Mark Gilreath, Founder and CEO at EndoChoice. “While 2013 has been an exciting year for our company, the introduction of Fuse into Canada and other markets will enable us to make 2014 even more dynamic as we bring this game-changing technology to more clinicians.” About EndoChoice Based in Atlanta, EndoChoice is a medtech company focused on the manufacturing and commercialization of platform technologies including devices, diagnostics, infection control and endoscopic imaging for specialists treating a wide range of gastrointestinal diseases. EndoChoice leverages its direct sales organization to serve more than 2,000 customers in the United States and works with 34 distribution partners world-wide. The Company was founded in 2008 and has rapidly developed a proprietary product portfolio, which includes the revolutionary Full Spectrum Endoscopy System (Fuse). 2013 marked the fourth consecutive year EndoChoice was recognized as one of the fastest growing companies in the U.S. by Inc.